Abbott (ABT) announced new Beta-CORRECT data presented at the European Society for Medical Oncology, or ESMO, Congress showing that the whole-genome sequencing, or WGS,-based Oncodetect molecular residual disease, or MRD, test achieved a 30% absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery, compared with the whole-exome sequencing, or WES, Oncodetect test, using a single post-surgery blood draw. A single blood test taken approximately one month after surgery using the WGS test achieved 72.2% sensitivity for recurrence within two years, compared with 42.2% for the WES test, a 30-percent absolute improvement. Among 157 patients tested post-surgery with both tests, the WGS test detected ctDNA in all 29 patients in whom the WES test identified, plus 15 additional patients. All additional detections were at levels below 20 parts per million, including 14 that were below 10 ppm. Strong prognostic value: Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence than ctDNA-negative patients. Two-year disease-free survival rates were 36.2% versus 92.3%, respectively. Patients with detectable post-surgical ctDNA had approximately 31-fold higher recurrence risk compared to those who were ctDNA negative. Only 2.8% of stage II patients with undetectable ctDNA experienced recurrence within two years. About the Oncodetect(R) test
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $120 from $124 at Evercore ISI
- Abbott price target raised to $120 from $119 at Wells Fargo
- Flyte Aviation’s suture retention device outperforms Abott’s Perclose
- Abbott price target lowered to $125 from $130 at RBC Capital
- Abbott price target lowered to $118 from $135 at TD Cowen